Vicore Pharma
Edit

Vicore Pharma

https://vicorepharma.com/
Last activity: 04.01.2024
Categories: DeliveryDevelopmentInformationITMarketMedtechPage
Vicore Pharma is a clinical-stage pharmaceutical company dedicated to creating life-changing treatments for severe lung diseases and related indications. The company currently has four development programs: VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and COVID-19. VP02 is based on a new formulation and delivery route of thalidomide and focuses on the severe, persistent cough associated with IPF. VP03 includes the development of new AT2R agonists. VP04 develops a clinically validated, CBT-based, digital therapeutic for IPF patients. The company's shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.
Followers
200
Mentions
146
Location: Sweden, Gothenburg
Employees: 11-50
Total raised: $19.37M
Founded date: 2009
Twitter
LinkedIn
Youtube
Email

Funding Rounds 1

DateSeriesAmountInvestors
09.12.2022-$19.37M-

Mentions in press and media 146

DateTitleDescriptionSource
04.01.2024Alex Therapeutics Reports Positive Results from the Randomiz...Alex Therapeutics and Vicore Pharma today announced positive results of the COMPANION study, investi...hadeanvent...
23.05.2023Vicore obtains significant new patent protection for C21 in ...Stockholm, May 23, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”) today announces issuance of...healthcap....
19.05.2023Vicore reports new 36-week data from the AIR trial demonstra...Stockholm, May 19, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a n...healthcap....
04.05.2023Interim report January-March 20232023-05-04| REGULATORY Stockholm, May 4, 2023 – Vicore Pharma Holding AB (publ), unlocking the pote...healthcap....
03.05.2023Vicore initiates clinical proof-of-concept study of endothel...Stockholm, May 3, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of...healthcap....
05.04.2023Vicore Pharma publishes the Annual Report for 2022Stockholm, April 5, 2023 –Vicore Pharma Holding AB (publ) (“Vicore” or “company”) unlocking the pote...healthcap....
01.04.2023Vicore to announce AIR trial update at the ATS congress on M...Stockholm, March 31, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a...healthcap....
30.03.2023Vicore receives Innovation Passport designation by the UK re...Stockholm, March 29, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a...healthcap....
28.02.2023Year-end report 2022Stockholm, February 28, 2023 – Vicore Pharma Holding AB (publ) publishes the year-end report for 202...healthcap....
30.12.2022Increase of number of shares and votes in Vicore PharmaIncrease of number of shares and votes in Vicore Pharma Fri, Dec 30, 2022 09:00 CET Report this con...news.cisio...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In